Mandaviya posted on Twitter, saying, “India’s Battle Against COVID-19 Gets a Huge Boost! The @CDSCO INDIA INF has approved Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine for primary COVID-19 immunization in the 18+ age range for very limited usage in emergency situations.”
According to Union Health Minister Dr. Mansukh Mandaviya, Bharat Biotech acquired emergency use authorization from DCGI for the intranasal Covid-19 vaccine on Tuesday.
He continued, “This will be the first nasal vaccine for Covid-19 in India.”
Mandaviya posted on Twitter, saying, “India’s Battle Against COVID-19 Gets a Huge Boost! The @CDSCO INDIA INF has approved Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine for primary COVID-19 immunization in the 18+ age range for very limited usage in emergency situations.”
The move, according to the health minister, will help India’s nationwide effort to combat the pandemic.
“Under the direction of PM @NarendraModi Ji, India has utilized its scientific, R&D, and human resources in the fight against COVID-19. We will beat COVID-19 with a science-driven strategy and Sabka Prayas “said he.
